So SPL have said in the past that they will license DEP irinotecan and DEP Cabazitaxel at Ph2 completion.
Each indication will be licensed separately.
So we would be looking at an upfront payment of $??
Annual Licensing payments of %??
Current TAM for
Ovarian = $3.5B rising to $6.1B in 2032 (US $)
Pancreatic = $2.86B rising to $10.69B 2032 (US$)
other indications….?
Ann: Positive final DEP irinotecan Phase 2 clinical trial results, page-27
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
